FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated breast cancerNov 6Regulatory decisionelacestrant
Context Therapeutics posts results for terminated elacestrant-onapristone breast cancer trialJul 21Trial updateContext Therapeutics Inc.elacestrant